King's College London

Research portal

AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.

Research output: Contribution to journalArticlepeer-review

Standard

AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study. / Harrison, John.

In: Nature Medicine, 01.03.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

Harrison, J 2021, 'AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.', Nature Medicine.

APA

Harrison, J. (Accepted/In press). AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study. Nature Medicine.

Vancouver

Harrison J. AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study. Nature Medicine. 2021 Mar 1.

Author

Harrison, John. / AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study. In: Nature Medicine. 2021.

Bibtex Download

@article{0ce33ed8e2d348cd8e16c955de89557c,
title = "AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.",
author = "John Harrison",
year = "2021",
month = mar,
day = "1",
language = "English",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.

AU - Harrison, John

PY - 2021/3/1

Y1 - 2021/3/1

M3 - Article

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454